TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07230834: A Phase 1 Dose-Escalation and Repeated-Dose Study of the Safety and Tolerability of Intravitreal Pozelimab in Participants With Geographic Atrophy

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 54 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,950,800

Rescue Site Savings

+$2,618,816

Unlock Full NCT07230834 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07230834 Rescue Dossier →